Information Provided By:
Fly News Breaks for April 13, 2016
ACUR
Apr 13, 2016 | 09:13 EDT
Roth Capital analyst Michael Higgins says the FDA designated Acura Pharmaceuticals' LTX-04 with Fast Track development, allowing an expedited review. Given the FDA's cautionary statements that current abuse deterrent formulations do not have impact on the primary form of abuse, swallowing too many opioids or taking them with alcohol, the designation is not surprising, but should alert to the importance of the Limitx technology, the analyst tells investors in a research note. Higgins reiterates a Buy rating and $6 price target.
News For ACUR From the Last 2 Days
There are no results for your query ACUR